menu search

ENTA / Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on March 14, 2023 at 10:00 a.m. ET. Read More
Posted: Mar 7 2023, 07:00
Author Name: Business Wire
Views: 102257

ENTA News  

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

By Business Wire
September 17, 2023

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, sma more_horizontal

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

By Seeking Alpha
August 7, 2023

Enanta Pharmaceuticals, Inc. (ENTA) Q3 2023 Earnings Call Transcript

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2023 Results Conference Call August 7, 2023 4:30 PM ET Company Participants Jennifer Viera - Investor R more_horizontal

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

By Zacks Investment Research
August 7, 2023

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Tops Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $2.38. This compares more_horizontal

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

By Market Watch
June 20, 2023

Enanta Pharmaceuticals shares gain after RSV treatment shows positive results in early trial

Shares of Enanta Pharmaceuticals Inc. ENTA, -0.25% gained 5% premarket on Tuesday after the biotech company released positive results from an early-ph more_horizontal

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

By Zacks Investment Research
May 8, 2023

Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates

Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $1.79 per share versus the Zacks Consensus Estimate of a loss of $1.91. This compares more_horizontal

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

By Business Wire
March 7, 2023

Enanta Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small mole more_horizontal


Search within

Pages Search Results: